Adaptyv EGFR Binder Design Competition 2
Design novel protein binders targeting and neutralizing EGFR, a cell-surface receptor that promotes uncontrolled cell growth in many cancers.
Overview
- Stage 1Computational Design
Submit your computational antibody designs. 200 designs will be selected for experimental validation, 100 by the best pAE_interaction,100 based on the rule of cool
Submissions OpenOct 4, 2024/
Submissions CloseNov 4, 2024 - Stage 2Experimental Validation
Selected designs undergo experimental validation in the Adaptyv Lab. Proteins with the highest binding affinity win the competition.
Validation startsNov 5, 2024/
Results releasedJan 15, 2025
- Stage 1Computational Design
Submit your computational antibody designs. 200 designs will be selected for experimental validation, 100 by the best pAE_interaction,100 based on the rule of cool
Submissions OpenOct 4, 2024/
Submissions CloseNov 4, 2024 - Stage 2Experimental Validation
Selected designs undergo experimental validation in the Adaptyv Lab. Proteins with the highest binding affinity win the competition.
Validation startsNov 5, 2024/
Results releasedJan 15, 2025
About the Target
EGFR
PDB: 1IVO
Sequence
Epidermal Growth Factor Receptor (EGFR) is a transmembrane protein that plays a critical role in cell growth, differentiation, and survival. It is frequently overexpressed or mutated in various cancers, including non-small cell lung cancer, colorectal cancer, and head and neck cancer. This makes EGFR a crucial target for cancer therapies such as Cetuximab, an antibody with more than 1B USD in annual revenue.
In this competition, you can continue testing your skills as a protein designer by leveraging data from Round 1. The challenge, as before is to find novel grade binders to EGFR_HUMAN. However this time, you should take their therapeutic power (effectively neutralizing EGFR by competively inhibiting the binding of epidermal growth factor (EGF) ).